<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>3D Molecule Generation from Rigid Motifs via SE(3) Flows - Health AI Hub</title>
    <meta name="description" content="This paper introduces a novel SE(3)-equivariant generative model for de novo 3D molecule generation that operates on rigid molecular motifs (fragments) instead ">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>3D Molecule Generation from Rigid Motifs via SE(3) Flows</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2601.16955v1" target="_blank">2601.16955v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2026-01-23
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Roman Poletukhin, Marcel Kollovieh, Eike Eberhard, Stephan G√ºnnemann
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.90 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2601.16955v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2601.16955v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a novel SE(3)-equivariant generative model for de novo 3D molecule generation that operates on rigid molecular motifs (fragments) instead of individual atoms. This fragment-based approach achieves comparable or superior performance to state-of-the-art atom-based methods, particularly in atom stability on the GEOM-Drugs benchmark, while significantly reducing generation steps and data representation size.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This method significantly accelerates and improves the process of designing novel 3D molecular structures, which is critical for de novo drug discovery and lead optimization, enabling quicker identification and generation of more stable potential therapeutic compounds.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>This AI model can be used to generate novel drug candidates with specific desired properties, accelerate lead compound identification, and optimize molecular structures for therapeutic efficacy and safety. By improving the efficiency and representation of molecule generation, it can significantly reduce the time and computational resources required to explore chemical space for potential medicines, thereby speeding up the drug development pipeline.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the limitation of atom-level 3D molecule generation by adopting a fragment-based approach, analogous to molecular graph generation techniques.</li>
                    
                    <li>Proposes a novel SE(3)-equivariant generative modeling framework, specifically utilizing 'SE(3) Flows,' for de novo 3D molecule generation.</li>
                    
                    <li>Represents molecules as collections of 'rigid-body motifs' (predefined fragments) rather than individual atoms, extending concepts from frame-based protein structure generation.</li>
                    
                    <li>Demonstrates competitive or superior performance against state-of-the-art atom-based methods on established benchmarks.</li>
                    
                    <li>Achieves significant improvement in atom stability, a crucial metric for drug design, on the GEOM-Drugs dataset.</li>
                    
                    <li>Offers substantial computational efficiency gains, including a 2x to 10x reduction in generation steps and a 3.5x compression in molecular representations compared to standard atom-based methods.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The authors employ SE(3)-equivariant generative modeling, leveraging 'SE(3) Flows,' to generate de novo 3D molecular structures. The core innovation lies in treating 'rigid-body motifs' (molecular fragments) as the fundamental building blocks instead of individual atoms, a strategy inspired by frame-based protein structure generation. This ensures that generated structures adhere to physical principles of 3D rotations and translations.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The proposed method yields comparable or superior results to state-of-the-art techniques across various benchmarks. A key finding is its superior performance in atom stability on the GEOM-Drugs dataset. Furthermore, it provides significant efficiency benefits, including a 2x to 10x reduction in generation steps and a 3.5x compression in molecular representations compared to standard atom-based methods.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The ability to generate stable and novel 3D molecular structures with significantly fewer computational steps and smaller data representations can dramatically accelerate the early stages of drug discovery and development. This could lead to a faster identification of potential drug candidates, enabling more efficient exploration of chemical space for therapeutics with improved stability and efficacy profiles, ultimately reducing the time and cost associated with bringing new drugs to market.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Not explicitly mentioned in the provided abstract. A full analysis of limitations would require reviewing the complete paper to understand aspects such as the scope and generalizability of the motif library, the complexity of molecules that can be effectively generated, and potential computational costs during model training.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Not explicitly mentioned in the provided abstract. Potential future work could involve expanding the diversity and size of the rigid motif library, integrating the generation process with specific drug design objectives (e.g., target specificity or ADMET properties), or exploring conditional generation based on desired molecular attributes.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Pharmaceutical Sciences</span>
                    
                    <span class="tag">Chemoinformatics</span>
                    
                    <span class="tag">Structural Biology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">3D molecule generation</span>
                    
                    <span class="tag tag-keyword">SE(3) Flows</span>
                    
                    <span class="tag tag-keyword">rigid motifs</span>
                    
                    <span class="tag tag-keyword">de novo drug design</span>
                    
                    <span class="tag tag-keyword">generative models</span>
                    
                    <span class="tag tag-keyword">molecular fragments</span>
                    
                    <span class="tag tag-keyword">computational chemistry</span>
                    
                    <span class="tag tag-keyword">atom stability</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Three-dimensional molecular structure generation is typically performed at the level of individual atoms, yet molecular graph generation techniques often consider fragments as their structural units. Building on the advances in frame-based protein structure generation, we extend these fragmentation ideas to 3D, treating general molecules as sets of rigid-body motifs. Utilising this representation, we employ SE(3)-equivariant generative modelling for de novo 3D molecule generation from rigid motifs. In our evaluations, we observe comparable or superior results to state-of-the-art across benchmarks, surpassing it in atom stability on GEOM-Drugs, while yielding a 2x to 10x reduction in generation steps and offering 3.5x compression in molecular representations compared to the standard atom-based methods.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>